Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

(Arg)9

Copy Product Info
😃Good
Catalog No. T13976Cas No. 143413-47-2
Alias Peptide R9, Nona-L-arginine

(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide,and exhibits neuroprotective activity(IC50 of 0.78 μM, in the glutamic acid model).

(Arg)9
Other Forms of (Arg)9:

(Arg)9

Copy Product Info
😃Good
Catalog No. T13976Alias Peptide R9, Nona-L-arginineCas No. 143413-47-2
(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide,and exhibits neuroprotective activity(IC50 of 0.78 μM, in the glutamic acid model).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
100 mgInquiry7-10 days7-10 days
500 mgInquiry7-10 days7-10 days
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide,and exhibits neuroprotective activity(IC50 of 0.78 μM, in the glutamic acid model).
Targets&IC50
Neuroprotection:0.78 μM
In vitro
Poly-arginine (e.g. (Arg)9) with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure with IC50 of 0.78 μM. Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model with IC50 of 0.81 μM. (Arg)9 also shows neuroprotection following in vitro ischemia with IC50 of 6 μM[1].
In vivo
In rat stroke models, (Arg)9) (D-isoform) is neuroprotective. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect[2]. (Arg) 9) (D-isoform) was administered intravenously at a dose of 1000 nmol/kg 30 minutes after permanent middle cerebral artery occlusion (MCAO) [3].
SynonymsPeptide R9, Nona-L-arginine
Chemical Properties
Molecular Weight1423.69
FormulaC54H110N36O10
Cas No.143413-47-2
SmilesNC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(O)=O
Relative Density.1.60 g/cm3 (Predicted)
SequenceArg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
Sequence ShortRRRRRRRRR
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

neuroprotection(Arg)9
Related Tags: buy (Arg)9 | purchase (Arg)9 | (Arg)9 cost | order (Arg)9 | (Arg)9 chemical structure | (Arg)9 in vivo | (Arg)9 in vitro | (Arg)9 formula | (Arg)9 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.